CN101668773B - 人工程化抗b因子抗体 - Google Patents

人工程化抗b因子抗体 Download PDF

Info

Publication number
CN101668773B
CN101668773B CN200880008123.2A CN200880008123A CN101668773B CN 101668773 B CN101668773 B CN 101668773B CN 200880008123 A CN200880008123 A CN 200880008123A CN 101668773 B CN101668773 B CN 101668773B
Authority
CN
China
Prior art keywords
seq
region
amino acid
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880008123.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN101668773A (zh
Inventor
W·艾米伦
V·M·郝勒斯
P·弗林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yalishi Cambridge Co
Original Assignee
Yalishi Cambridge Co</en>
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yalishi Cambridge Co</en> filed Critical Yalishi Cambridge Co</en>
Publication of CN101668773A publication Critical patent/CN101668773A/zh
Application granted granted Critical
Publication of CN101668773B publication Critical patent/CN101668773B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200880008123.2A 2007-03-14 2008-03-14 人工程化抗b因子抗体 Expired - Fee Related CN101668773B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90681607P 2007-03-14 2007-03-14
US60/906,816 2007-03-14
PCT/US2008/003381 WO2008140653A2 (en) 2007-03-14 2008-03-14 Humaneered anti-factor b antibody

Publications (2)

Publication Number Publication Date
CN101668773A CN101668773A (zh) 2010-03-10
CN101668773B true CN101668773B (zh) 2016-08-31

Family

ID=40002836

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880008123.2A Expired - Fee Related CN101668773B (zh) 2007-03-14 2008-03-14 人工程化抗b因子抗体

Country Status (9)

Country Link
US (3) US7964705B2 (enExample)
EP (3) EP2118142A2 (enExample)
JP (2) JP5872757B2 (enExample)
CN (1) CN101668773B (enExample)
AU (1) AU2008251943B2 (enExample)
BR (1) BRPI0808227A2 (enExample)
CA (1) CA2680344A1 (enExample)
ES (1) ES2507542T3 (enExample)
WO (1) WO2008140653A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1713503T3 (da) 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
ES2548700T3 (es) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
AU2007261315B2 (en) 2006-06-21 2012-10-25 Musc Foundation For Research Development Targeting complement factor H for treatment of diseases
AU2008251943B2 (en) 2007-03-14 2013-09-05 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
US20110160636A1 (en) * 2008-09-10 2011-06-30 Rekha Bansal Device and method for inhibiting complement activation
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4 Inc Posterior segment drug delivery
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
EA201290286A1 (ru) 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
SG185483A1 (en) 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
EP2585110A4 (en) 2010-06-22 2014-01-22 Univ Colorado Regents ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3
US20130324482A1 (en) * 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
HUE057267T2 (hu) * 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
EP2640360A2 (en) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
WO2013091903A1 (en) * 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
EP2834271B1 (en) * 2012-04-03 2019-01-16 NovelMed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
SG10202104175YA (en) 2014-02-27 2021-06-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2020210512A1 (en) 2019-04-09 2020-10-15 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
MX2022001309A (es) * 2019-07-30 2022-05-10 Immunome Inc Anticuerpos específicos il-38.
KR102509648B1 (ko) * 2019-08-06 2023-03-15 아프리노이아 테라퓨틱스 리미티드 병리학적 타우 종에 결합하는 항체 및 이의 용도
JP6982129B2 (ja) * 2020-04-27 2021-12-17 田中貴金属工業株式会社 抗水痘帯状疱疹ウイルス抗体、免疫学的測定方法及び免疫学的測定用装置
US20230331853A1 (en) * 2020-09-11 2023-10-19 National Jewish Health Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells
KR20240004375A (ko) * 2021-03-28 2024-01-11 이뮤놈 인코포레이티드 Il-38-특이적 항체
JP2024520497A (ja) 2021-05-28 2024-05-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｃｍ－ｔｍａバイオマーカーを検出するための方法
KR20250158063A (ko) 2023-03-16 2025-11-05 젠자임 코포레이션 건식 연령-관련 황반 변성의 치료

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845083A (en) 1983-10-05 1989-07-04 Merck Frosst Canada, Inc. Method of inhibiting mammalian leukotriene biosynthesis
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
EP0512733A2 (en) * 1991-05-03 1992-11-11 Washington University Modified complement system regulator
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
US5976540A (en) * 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5869615A (en) * 1994-01-03 1999-02-09 Washington University Modified complement proteases
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
GB9624731D0 (en) * 1996-11-28 1997-01-15 Univ Leicester Complement inhibitor
US6333034B1 (en) * 1997-08-26 2001-12-25 Gliatech, Inc. Process for inhibiting complement activation via the alternative pathway
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
DE69939813D1 (de) 1998-02-20 2008-12-11 Tanox Inc Inhibitoren der komplement-aktivierung
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
GB9930659D0 (en) 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
US20040014782A1 (en) 2002-03-29 2004-01-22 Krause James E. Combination therapy for the treatment of diseases involving inflammatory components
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP1545611B1 (en) 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
WO2004031240A1 (en) 2002-10-04 2004-04-15 Stichting Sanquin Bloedvoorziening Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
EP2292259A3 (en) 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
JP2006518750A (ja) * 2003-02-21 2006-08-17 リクスホスピタレット−ラジウムホスピタレット・ホーエフ 胎便吸引症候群の治療のための方法および組成物
US20070123466A1 (en) 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
JP4772667B2 (ja) 2003-06-02 2011-09-14 エヴォルーテック・リミテッド 補体阻害剤
WO2005003159A1 (en) 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
US7638481B2 (en) 2003-09-05 2009-12-29 University Of Louisville Research Foundation, Inc. Treatment of spinal cord injury
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
EP1761561B1 (en) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
EP1713503B1 (en) * 2004-02-10 2013-07-31 The Regents of the University of Colorado, a Body Corporate Inhibition of factor b, the alternative complement pathway and methods related thereto
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
WO2005113863A2 (en) * 2004-05-20 2005-12-01 Valence Technology, Inc. Secondary electrochemical cell
US20090004183A1 (en) 2004-07-23 2009-01-01 Taylor Ronald P Compositions and Methods for Regulating the Alternative Pathway of Complement
CA2578613A1 (en) 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
WO2006055178A2 (en) * 2004-10-25 2006-05-26 Merck & Co., Inc. Anti-addl antibodies and uses thereof
AU2005306502B2 (en) * 2004-11-16 2012-11-15 Humanigen, Inc. Immunoglobulin variable region cassette exchange
WO2006062716A2 (en) 2004-11-18 2006-06-15 Yale University Methods and compositions for treating ocular disorders
WO2006083533A2 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
EP2357257B1 (en) * 2005-02-14 2019-07-31 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
ES2548700T3 (es) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
CN101262855A (zh) 2005-09-08 2008-09-10 帝斯曼知识产权资产管理有限公司 治疗或预防年龄相关性黄斑变性的方法
WO2007032876A2 (en) 2005-09-09 2007-03-22 University Of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
AU2007261315B2 (en) 2006-06-21 2012-10-25 Musc Foundation For Research Development Targeting complement factor H for treatment of diseases
AU2008251943B2 (en) 2007-03-14 2013-09-05 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US20090175847A1 (en) * 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
KR100951695B1 (ko) 2007-12-24 2010-04-07 (주)페타리 아이솔레이터 및 그 제조 방법
US7964105B2 (en) 2008-08-07 2011-06-21 William Harris Moss Method for improving belt press dewatering
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
EA201290286A1 (ru) 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
SG185483A1 (en) 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
EP2585110A4 (en) 2010-06-22 2014-01-22 Univ Colorado Regents ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.TAUBE et.al.Factor B of the alternative complement pathway regulates develpment of airway hyperresponsiveness and inflammation.《PANA》.2006,第103卷(第21期),8084-8089. *

Also Published As

Publication number Publication date
JP2014133753A (ja) 2014-07-24
EP2236518A2 (en) 2010-10-06
EP2236518B1 (en) 2014-08-06
JP2010521470A (ja) 2010-06-24
US20110318337A1 (en) 2011-12-29
US9096677B2 (en) 2015-08-04
US7964705B2 (en) 2011-06-21
AU2008251943A1 (en) 2008-11-20
HK1144948A1 (en) 2011-03-18
JP5872757B2 (ja) 2016-03-01
EP2118142A2 (en) 2009-11-18
WO2008140653A2 (en) 2008-11-20
EP2565207A2 (en) 2013-03-06
WO2008140653A3 (en) 2009-04-02
BRPI0808227A2 (pt) 2014-07-08
CN101668773A (zh) 2010-03-10
US20080299114A1 (en) 2008-12-04
EP2565207A3 (en) 2013-06-12
AU2008251943B2 (en) 2013-09-05
US20130216529A1 (en) 2013-08-22
ES2507542T3 (es) 2014-10-15
EP2236518A3 (en) 2010-12-01
CA2680344A1 (en) 2008-11-20
WO2008140653A9 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
CN101668773B (zh) 人工程化抗b因子抗体
US9725522B2 (en) Pulmonary administration of immunoglobulin single variable domains and constructs thereof
JP5137053B2 (ja) 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬
EP2744822B1 (en) Modified proteins and peptides
US10858446B2 (en) Anti-PCSK9 antibodies and uses thereof
JP2020127430A (ja) 抗プロ／潜在型−ミオスタチン抗体およびその使用
EP4198055A1 (en) Antibody of il-11 and use thereof
US20170174778A1 (en) pH Dependent Antibodies Targeting the Transferrin Receptor
US9803005B2 (en) Humaneered anti-factor B antibody
AU2005212369B2 (en) Inhibition of factor B, the alternative complement pathway and methods related thereto
US20220073596A1 (en) Method for the treatment of idiopathic pulmonary fibrosis
JP2016007218A (ja) 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
EP4537907A1 (en) Cd248 inhibitors and uses thereof
CN101022828B (zh) B因子、补体旁路的抑制及与此相关的方法
HK1144948B (en) Humaneered anti-factor b antibody
WO2025026216A1 (zh) 一种含有糖皮质激素的抗体药物偶联物的药物组合物
HK40027205B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: YALISHI CAMBRIDGE CO.

Free format text: FORMER OWNER: TALIGEN THERAPEUTICS INC.

Effective date: 20130115

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130115

Address after: Massachusetts, USA

Applicant after: Taligen Therapeutics, Inc

Address before: Massachusetts, USA

Applicant before: Taligen Therapeutics Inc.

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: American Connecticut

Applicant after: Taligen Therapeutics, Inc

Address before: Massachusetts, USA

Applicant before: Taligen Therapeutics, Inc

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151111

Address after: Delaware

Applicant after: Yalishi Cambridge Co.

Address before: American Connecticut

Applicant before: Taligen Therapeutics, Inc

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160831

Termination date: 20170314